Caricamento...

Vorinostat increases carboplatin and paclitaxel activity in non-small cell lung cancer cells

We observed a 53% response rate in non-small cell lung cancer (NSCLC) patients treated with vorinostat plus paclitaxel/carboplatin in a Phase I trial. Studies were undertaken to investigate the mechanism (s) underlying this activity. Growth inhibition was assessed in NSCLC cells by MTT assay after 7...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Owonikoko, Taofeek K., Ramalingam, Suresh S., Kanterewicz, Beatriz, Balius, Trent, Belani, Chandra P., Hershberger, Pamela A.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2010
Soggetti:
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2795066/
https://ncbi.nlm.nih.gov/pubmed/19621389
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.24759
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !